Journal of Mid-life Health Journal of Mid-life Health
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission | Subscribe | Advertise Users Online: 175  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 

 Table of Contents 
Year : 2022  |  Volume : 13  |  Issue : 2  |  Page : 185-189  

Counselling for testosterone therapy in mid life men

1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Department of Endocrinology, Bhaktivedanta Hospital, Mumbai, Maharashtra, India
3 Department of Endocrinology, Bansal Hospital, Sri Ganganagar, Rajasthan, India
4 Department of Endocrinology, Cedar Clinic, New Delhi, India
5 Department of Endocrinology, Apollo Hospital; Department of Endocrinology, Tech Medical College, Bhubaneshwar, Odisha, India

Date of Submission09-Oct-2020
Date of Decision15-Jan-2021
Date of Acceptance21-Jul-2021
Date of Web Publication16-Sep-2022

Correspondence Address:
Sanjay Kalra
Department of Endocrinology, Bharti Hospital, Kunjpura Road, Karnal - 132 001, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmh.jmh_240_20

Rights and Permissions

Testosterone is frequently used for the optimization of mid-life health. This therapy is effective and safe if accompanied by adequate counseling, before prescription, and during administration. In this opinion piece, we discuss the style and substance of medication counseling for testosterone therapy. The role and scope of counseling are highlighted, with a focus on screening, diagnosis, medication counseling, sexual counseling, and monitoring. This article should prove useful for all health care professionals.

Keywords: Androgen, androgen deficiency, andropause, hormonal replacement therapy, medication counseling, sexual counseling, testosterone

How to cite this article:
Kalra S, Joshi A, Dhingra A, Dutta D, Das S. Counselling for testosterone therapy in mid life men. J Mid-life Health 2022;13:185-9

How to cite this URL:
Kalra S, Joshi A, Dhingra A, Dutta D, Das S. Counselling for testosterone therapy in mid life men. J Mid-life Health [serial online] 2022 [cited 2022 Oct 6];13:185-9. Available from:

   Introduction Top

Testosterone is indicated for the management of testosterone deficiency. While there are many etiologies of this dysfunction, the most common is age-related. Andropause, better known as (androgen deficiency in the aging male) presents with a wide variety of biomedical as well as psychosocial challenges. While some of these may be related to aging in general, others are specifically linked to a decline in testosterone levels.[1]

Metabolic disorders, such as diabetes, obesity, metabolic syndrome, obstructive sleep apnea; medical disorders such as anemia, chronic liver disease, chronic kidney disease, chronic lung disease, HIV/acquired immunodeficiency syndrome; endocrine disorders including osteoporosis, sarcopenia, pituitary disease; history of chronic corticosteroid use, anabolic androgenic substance abuse, antipsychotic/anticonvulsant therapy, gonadal radiation, and gonadal surgery can be associated with low testosterone levels.

   The Role of Counselling Top

Although various pharmacological options are available for the management of testosterone deficiency, and its associated comorbidities, counseling is an essential part of the management of andropause.[2] Counseling acts as a therapy in itself, as explained in the concept of therapeutic patient education. Counseling also improves understanding or acceptance of, and adherence to suggested therapy.[3] It improves satisfaction with treatment, enhances patient-physician bonding, and works as (value-added therapy).

   The Scope of Counseling Top

Although the term counseling is defined as “the provision of professional assistance and guidance in resolving personal or psychological problems,” it has a much broader connotation in medicine.[4] Medication counseling can be defined as the process of assessment of patient needs, preferences, and wishes; enhancing awareness, sharing of advice, allaying of concerns, and offering assistance as required, in relation to prescribed medication, to optimize acceptance of, and adherence to therapy. Medication counseling is an integral part of andropause management.[3],[5]

Andropause counseling includes, and overlaps with, patient education, support, advocacy, and medication counseling. [Table 1] lists the various facets of andropause counseling. Many of these facets are similar to those seen with other chronic diseases.[6] A few aspects of counseling, however, need specific attention, as they are specific to andropause. These are medication counseling for testosterone therapy and sexual counseling.
Table 1: Domains of andropause counseling

Click here to view

   Screening and Diagnosis Top

Counseling begins simultaneously with screening. Though universal screening for testosterone deficiency is not recommended, assessment of testosterone adequacy should be done if symptoms, signs, or surrogate laboratory markers are suggestive.[7],[8] While monitoring is ideally done by measuring testosterone levels at appropriate intervals, it should be supplemented with clinical interviewing. Libido, erectile function, hemoglobin, bone mineral density, lean body mass, and depressive symptoms can be used as clinical markers for screening as well as monitoring. Validated screening tools [Table 2] can be used for monitoring of symptomatic well-being as well.
Table 2: Questionnaires that may be used to kickstart a conversation, screen, and/or monitor testosterone deficiency

Click here to view

   Cost Benefit Ratio/Reality Check Top

Before starting therapy, the patient should be explained regarding expected benefits, limitations, and caveats of testosterone therapy. Unfounded concerns should be allayed. At the same time, the patient should be provided with a realistic idea of which symptoms, signs, and abnormalities he can expect benefit in. There is no link of testosterone therapy with venous thromboembolism. Its impact on cognitive function, glycemic control, energy level/quality of life, and lipid health/cardiovascular health is uncertain. One must always be watchful for the potential deleterious effects on polycythemia and spermatogenesis. Some contraindications are active prostatic carcinoma, acute coronary syndromes in the past 3–6 months, and heart failure NYHA Class IV.

   Medication Counseling Top

Testosterone is the pillar of andropause management. Various preparations of testosterone are available: Some of these are listed in [Table 3]. These formulations differ in their route of administration, onset and duration of action, potency, and expected side effects or limitations.[15] Therefore, knowledge of the clinical pharmacology of various androgenic drugs can be utilized to craft a person-centered choice of therapy. This knowledge forms the basis of the content of andropause counseling.
Table 3: Testosterone preparation in the Indian market

Click here to view

The British Society for Sexual Medicine guidelines on adult testosterone deficiency leave the choice of preparation to the patient.[16] Even for this, however, information equipoise is necessary to ensure the optimal choice of treatment modality. This can be done through detailed medication counseling. The Endocrine Society (2018) suggests patient preference, formulation pharmacokinetics, treatment burden, and cost as determinants of the choice of therapy.[7],[17]

Prescription of injectable testosterone presumes the availability of qualified and experienced health-care professionals capable of administering the drug. This consideration is especially important while using testosterone undecanoate, which is injected as a 4 ml oily suspension. In case of difficulty, 2 ml of this drug can be injected into each buttock.[15]

[Table 4] describes some important points which must be kept in mind while planning a person-centric testosterone therapy in andropause. Clinical response/well-being, testosterone levels, hematocrit, prostate health, (prostate-specific antigen), digital rectal examination, and prostate ultrasonography may be used to monitor testosterone therapy at regular intervals.[8],[15]
Table 4: Person-specific choice of testosterone therapy

Click here to view

Although not related to andropause, it is pertinent to mention that transgender persons (transmen) also use testosterone as gender-affirmative therapy.[18] Such persons have special needs and must be handled in a gender-friendly manner. Transmen will require just 50%–75% of normal dosage to achieve masculinization and are more susceptible to side effects such as acne.

   Sexual Counseling Top

Sexual dysfunction is the sine qua non of andropause, and sexual counseling, an integral part of andropause care. Reader-friendly guidance on how to elicit a sexual history, and the steps of sexual counseling are available.[19] [Table 5] and [Table 6] describe the style as well as the content of sexual counseling. The man in andropause, who is usually in mid-life, will require more confidence building and support from the health-care professional. A greater emphasis on metabolic and medical optimization, as opposed to focus limited to psychosocial support, maybe in order. Counseling of the man in andropause should also include explanation of cardiac-friendly and “musculo-skeletally non demanding” ways of achieving sexual satisfaction.[19]
Table 5: Water approach to motivational interviewing in sexual counseling

Click here to view
Table 6: Nonverbal cues indicating sexual discomfort

Click here to view

Though fertility is rarely an issue in this age group, the health-care professional should enquire about the person's needs and wishes. One may suggest contraceptive measures or fertility augmenting treatment as deemed appropriate. Counseling should also include a discussion on the prevention of sexually transmitted diseases as well as genital tract infections, The need to maintain genital hygiene, especially in men on sodium-glucose co-transporter 2 inhibitors, should also be stressed.[20]

   Summary Top

Testosterone is frequently used for the optimization of mid-life health. This therapy is effective and safe if accompanied by adequate counseling, before prescription, and during administration. This article provides a comprehensive overview of testosterone counseling, and should prove useful for all health-care professionals.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Singh P. Andropause: Current concepts. Indian J Endocrinol Metab 2013;17:S621-9.  Back to cited text no. 1
Brawer MK. Testosterone replacement in men with andropause: An overview. Rev Urol 2004;6 Suppl 6:S9-15.  Back to cited text no. 2
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86:304-14.  Back to cited text no. 3
Oxford English and Spanish Dictionary, Thesaurus, and Spanish to English Translator. Available from: [Last accessed on 2020 Sep 30].  Back to cited text no. 4
Say RE, Thomson R. The importance of patient preferences in treatment decisions – Challenges for doctors. BMJ 2003;327:542-5.  Back to cited text no. 5
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96.  Back to cited text no. 6
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103:1715-44.  Back to cited text no. 7
Salonia A, Rastrelli G, Hackett G, Seminara SB, Huhtaniemi IT, Rey RA, et al. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 2019;5:38.  Back to cited text no. 8
Heineman AJ, Zimmermann J, Vermeulen A, Thiel C. A new aging males' symptoms (AMS) rating scale. Aging Male 1998;2:105-14.  Back to cited text no. 9
Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Chiarini V, et al. ANDROTEST: A structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 2006;3:706-15.  Back to cited text no. 10
Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-42.  Back to cited text no. 11
Mohamed O, Freundlich RE, Dakik HK, Grober ED, Najari B, Lipshultz LI, et al. The quantitative ADAM questionnaire: A new tool in quantifying the severity of hypogonadism. Int J Impot Res 2010;22:20-4.  Back to cited text no. 12
Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000;53:703-11.  Back to cited text no. 13
Gelhorn HL, Dashiell-Aje E, Miller MG, DeRogatis LR, Dobs A, Seftel AD, et al. Psychometric evaluation of the hypogonadism impact of symptoms questionnaire. J Sex Med 2016;13:1737-49.  Back to cited text no. 14
Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol 2016;5:834-43.  Back to cited text no. 15
Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, et al. British society for sexual medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med 2017;14:1504-23.  Back to cited text no. 16
Maganty A, Shoag JE, Ramasamy R. Testosterone threshold-Does one size fit all? Aging Male 2015;18:1-4.  Back to cited text no. 17
Lim HH, Jang YH, Choi GY, Lee JJ, Lee ES. Gender affirmative care of transgender people: A single center's experience in Korea. Obstet Gynecol Sci 2019;62:46-55.  Back to cited text no. 18
Kalra S, Balhara YP, Baruah M, Saxena A, Makker G, Jumani D, et al. Consensus guidelines on male sexual dysfunction. J Med Nutr Nutraceuticals 2013;2:5.  Back to cited text no. 19
Unnikrishnan AG, Kalra S, Purandare V, Vasnawala H. Genital infections with sodium glucose cotransporter-2 inhibitors: Occurrence and management in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab 2018;22:837-42.  Back to cited text no. 20


  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    The Role of Coun...
    The Scope of Cou...
    Screening and Di...
    Cost Benefit Rat...
    Medication Couns...
   Sexual Counseling
    Article Tables

 Article Access Statistics
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal